Ann: Successful BARD1 Kit Evaluation, page-35

I have never, and still don't, deny the potential here.
Its actually mind boggling if we get to market with a blood test for Ovarian. Breast and Lung cancer.
The market for this is soooo big that I can't see BD1 surviving long term if all goes to plan.
The big take away from the last announcement is the test is simpler than before. So often these things get harder....not easier. I think its a big step forward.
I'd love to know how many peptides it was reduced to. Hinch told me the current test was 22 some time ago.
Is it now 20...or 10...or 5?
The less the better IMO.

I am negative on the SDX deal because I think it was way over priced and I have seen zero evidence it has offered anything of value to this point.
The market seems to agree.
The sp is about the same as before the deal but with a lot more shares on issue.
I think this is the real hand brake IMO.
I will be watching the quarterly spend V income to see if SDX sales add any significant uplift in income.
Given the test is going to Queensland to be verified I'm not sure SDX lab in Melbourne is of any benefit atm.